Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
aka CLOVER-1
A phase 2 trial of Iopofosine I 131 single dose in waldenström macroglobulinaemia, multiple myeloma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma, run by Cellectar Biosciences, Inc., active and no longer recruiting.
Overview
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom is a phase 2 interventional study registered as NCT02952508 by Cellectar Biosciences, Inc., with 120 participants enrolled, started 2017-07-26 and due to reach its primary completion in 2026-06-22. Interventions recorded: Iopofosine I 131 single dose, Iopofosine I 131 multiple dose and Iopofosine I 131 fractionated dose.
Setting
An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)
Phase
Phase 2
Sponsor
Cellectar Biosciences, Inc.
Registry
Enrolled
120 enrolled
Similar pages
not linked directly; found by shared links- AgentIomab-B
Shares Iodine-131 and the tag pipeline.